

## **Middle East and Africa In-vitro Diagnostics Market Report and Forecast 2024-2032**

Market Report | 2024-09-30 | 150 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$3999.00
- Five User License \$5299.00
- Corporate License \$6299.00

### **Report description:**

Middle East and Africa In-vitro Diagnostics Market Report and Forecast 2024-2032

The Middle East and Africa in-vitro diagnostics market was valued at USD 4.3 billion in 2023. It is expected to grow at a CAGR of 5% during the period 2024-2032 and attain a market value of USD 6.6 billion by 2032.

Middle East and Africa In-vitro Diagnostics Market Analysis

The Middle East and Africa (MEA) in-vitro diagnostics (IVD) market is a rapidly evolving sector within the healthcare industry. IVD tests are critical in diagnosing and monitoring various health conditions, offering timely and accurate information that guides clinical decision-making. This market encompasses a range of diagnostic devices and reagents used to analyse biological samples such as blood, urine, and tissue. The increasing prevalence of chronic diseases, advancements in diagnostic technologies, and the growing importance of early diagnosis are significant factors driving the market's growth.

#### Market Drivers

**Rising Prevalence of Chronic Diseases:** The MEA region faces a high burden of chronic diseases such as diabetes, cardiovascular diseases, and cancer. The growing incidence of these conditions necessitates advanced diagnostic tools to ensure early detection and effective management, thereby boosting the demand for IVD.

**Technological Advancements:** Innovations in diagnostic technologies, including molecular diagnostics, point-of-care testing, and next-generation sequencing, are enhancing the accuracy and efficiency of IVD tests. These advancements are driving the adoption of IVD solutions across the region.

**Increasing Healthcare Expenditure:** Governments and private entities in the MEA region are investing heavily in healthcare infrastructure and services. This increased expenditure is facilitating the adoption of advanced diagnostic tools and expanding

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

access to healthcare services, thereby propelling market growth.

**Growing Awareness and Screening Programs:** Initiatives to increase awareness about the importance of early diagnosis and regular health check-ups are gaining traction. Screening programs for various diseases, supported by governmental and non-governmental organisations, are significantly contributing to the growth of the IVD market.

## Challenges

**Economic Disparities:** The MEA region is characterised by significant economic disparities, with some countries having well-developed healthcare systems while others face severe resource constraints. This economic divide affects the uniform adoption of advanced diagnostic technologies across the region.

**Regulatory and Reimbursement Issues:** Variations in regulatory frameworks and reimbursement policies across different countries in the MEA region pose challenges to the market. The lack of harmonised regulations and complex approval processes can hinder the timely introduction of new IVD products.

**Limited Skilled Workforce:** The shortage of skilled healthcare professionals, particularly in rural and underserved areas, is a major challenge. This scarcity affects the effective utilisation of IVD technologies and limits the market's potential growth.

## Future Opportunities

**Expansion of Point-of-Care Testing:** Point-of-care testing (POCT) offers the advantage of immediate results and convenience, particularly in remote and underserved regions. The expansion of POCT solutions presents a significant growth opportunity for the IVD market in the MEA region.

**Integration of AI and Machine Learning:** The incorporation of artificial intelligence (AI) and machine learning in diagnostic processes can enhance the accuracy and efficiency of IVD tests. Developing AI-driven diagnostic tools tailored to the specific needs of the MEA market could drive significant advancements.

**Public-Private Partnerships:** Collaborations between governments, non-governmental organisations, and private companies can address the challenges of economic disparities and regulatory complexities. These partnerships can facilitate the development and distribution of affordable and accessible IVD solutions.

**Focus on Infectious Diseases:** The MEA region is prone to infectious diseases such as HIV, tuberculosis, and malaria. The development of innovative diagnostic tools for the early detection and management of these diseases presents a substantial market opportunity.

**Telemedicine and Remote Diagnostics:** The growing adoption of telemedicine and remote diagnostics can bridge the gap in healthcare access in the MEA region. Integrating IVD solutions with telehealth platforms can enhance diagnostic capabilities and reach a broader population.

## Middle East and Africa In-vitro Diagnostics Market Trends

The Middle East and Africa (MEA) in-vitro diagnostics (IVD) market is undergoing significant transformation, driven by advancements in diagnostic technologies and increasing healthcare needs. Understanding the latest market trends is essential for stakeholders to navigate this dynamic landscape effectively.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Market Trends

**Shift Towards Personalised Medicine:** The IVD market in the MEA region is witnessing a growing emphasis on personalised medicine. Tailoring diagnostic tests to individual patient profiles is enhancing treatment outcomes and driving the demand for specialised diagnostic solutions.

**Rise of Point-of-Care Testing (POCT):** Point-of-care testing is gaining traction due to its ability to provide rapid results and improve patient management, especially in remote and underserved areas. This trend is expected to significantly contribute to market growth.

**Integration of Digital Health Technologies:** The adoption of digital health technologies, including telemedicine and mobile health applications, is transforming the IVD landscape. These technologies facilitate remote diagnostics and real-time monitoring, improving healthcare accessibility and efficiency.

**Increased Focus on Infectious Disease Diagnostics:** Given the region's susceptibility to infectious diseases such as malaria, tuberculosis, and HIV, there is a heightened focus on developing advanced diagnostic tools for early detection and management of these conditions.

**Advancements in Molecular Diagnostics:** Molecular diagnostics are becoming increasingly popular due to their high sensitivity and specificity. Innovations in this area, including next-generation sequencing and polymerase chain reaction (PCR) techniques, are driving market growth.

**Expansion of Laboratory Automation:** Laboratory automation is being adopted to improve accuracy, efficiency, and throughput in diagnostic processes. Automated systems are reducing human error and operational costs, making them attractive investments for healthcare providers.

## Middle East and Africa In-vitro Diagnostics Market Segmentation

### Market Breakup by Product Type

Reagents and Kits

Instruments

Software and Services

The Middle East and Africa in-vitro diagnostics (IVD) market is segmented into reagents and kits, instruments, and software and services. Reagents and kits dominate due to their extensive use in diagnostic tests, driven by the rising prevalence of chronic diseases. Instruments are witnessing growth due to technological advancements and the increasing adoption of automated systems. Software and services are expanding rapidly, fuelled by the integration of AI and data analytics, enhancing diagnostic accuracy and efficiency. These segments collectively propel market growth, with a forecasted increase due to advancements in

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

technology, rising healthcare awareness, and a growing emphasis on early disease detection.

#### Market Breakup by Technology

Immunoassay/ Immunochemistry

Clinical Chemistry?

Molecular Diagnostics

Haematology

Microbiology

Blood Glucose Self-Monitoring

Coagulation and Haemostasis

Urinalysis

Others

The Middle East and Africa in-vitro diagnostics (IVD) market is segmented by technology into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, haematology, microbiology, blood glucose self-monitoring, coagulation and haemostasis, urinalysis, and others. Immunoassays and immunochemistry lead due to their widespread application in disease detection and monitoring. Molecular diagnostics is growing rapidly, driven by advancements in genetic testing and personalised medicine. Clinical chemistry and haematology benefit from routine use in hospitals and laboratories. Blood glucose self-monitoring sees significant demand due to rising diabetes prevalence. The growth in these technologies is poised to drive market expansion, emphasising technological innovation and improved healthcare outcomes.

#### Market Breakup by Therapeutic Area

Infectious Diseases

Diabetes

Cardiology

Oncology

Autoimmune Diseases

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Nephrology

Others

The Middle East and Africa in-vitro diagnostics (IVD) market is segmented by therapeutic area into infectious diseases, diabetes, cardiology, oncology, autoimmune diseases, nephrology, and others. Infectious diseases dominate due to the ongoing need for rapid and accurate diagnostic tests, especially highlighted by the COVID-19 pandemic. Diabetes diagnostics see sustained demand driven by the high prevalence of the condition. Cardiology and oncology are experiencing growth due to advancements in biomarkers and personalised medicine approaches. Autoimmune diseases and nephrology segments are expanding as awareness and early diagnosis improve. These therapeutic areas collectively drive market growth, emphasising the importance of early and precise disease detection.

#### Market Breakup by End User

Hospitals

Laboratories

Homecare

Others

The Middle East and Africa in-vitro diagnostics (IVD) market is segmented by end user into hospitals, laboratories, homecare, and others. Hospitals dominate due to the high volume of diagnostic tests performed in these settings, driven by the need for accurate and timely disease diagnosis. Laboratories also hold a significant share, benefiting from advancements in automation and high-throughput technologies. Homecare diagnostics are rapidly growing, spurred by the increasing preference for convenient and cost-effective home-based testing, particularly for chronic disease management. These end-user segments collectively propel market growth, with innovations in technology and a focus on patient-centric care driving future expansion.

#### Market Breakup by Country

Saudi Arabia

United Arab Emirates

Nigeria

South Africa

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Others

The Middle East and Africa in-vitro diagnostics (IVD) market is segmented by country into Saudi Arabia, the United Arab Emirates, Nigeria, South Africa, and others. Saudi Arabia and the UAE lead due to advanced healthcare infrastructure and government investments in healthcare technology. Nigeria and South Africa show significant growth potential, driven by rising healthcare awareness and increasing prevalence of infectious diseases. The overall market is poised for expansion, fuelled by economic growth, improving healthcare access, and technological advancements. These countries collectively drive market growth, with a focus on enhancing diagnostic capabilities and early disease detection during the forecast period.

## Middle East and Africa In-vitro Diagnostics Market Competitive Landscape

The Middle East and Africa in-vitro diagnostics (IVD) market features a competitive landscape with key players such as F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Siemens Healthineers AG, bioMerieux SA, Abbott Laboratories, Quidel Corporation, OraSure Technologies, Inc., Thermo Fisher Scientific Inc, Hologic, Inc., Cepheid Inc (Danaher Corp.), and Illumina, Inc. Market activities include frequent mergers and acquisitions aimed at expanding product portfolios and market reach. Research initiatives and product introductions are common, focusing on innovative diagnostic solutions and advanced technologies. Partnerships and collaborations are strategic, enhancing market presence and driving growth in this region.

## Key Questions Answered in the Report

What is the current and future performance of the Middle East and Africa In-vitro Diagnostics market?

What are the main challenges facing the Middle East and Africa In-vitro Diagnostics market?

What are the key drivers of the Middle East and Africa In-vitro Diagnostics market?

What emerging trends are shaping the future of the Middle East and Africa In-vitro Diagnostics market?

How is the trend towards personalised medicine influencing the development of companion diagnostics?

Why do reagents and kits dominate the IVD market, and how are instruments evolving?

How are molecular diagnostics, clinical chemistry, and haematology evolving in the IVD market?

What factors are driving the sustained demand for diabetes diagnostics?

Why do hospitals dominate the IVD market in terms of diagnostic test volumes?

## Key Benefits for Stakeholders

The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Middle East and Africa In-vitro Diagnostics market from 2017-2032.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The research report provides the latest information on the market drivers, challenges, and opportunities in the Middle East and Africa In-vitro Diagnostics market.

The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.

Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Middle East and Africa In-vitro Diagnostics industry and its attractiveness.

The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

## **Table of Contents:**

- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 In-vitro Diagnostics Market Overview
- 3.1 Global In-vitro Diagnostics Market
- 3.1.1 Global In-vitro Diagnostics Market Historical Value (2017-2023)
- 3.1.2 Global In-vitro Diagnostics Market Forecast Value (2024-2032)
- 3.2 Middle East and Africa In-vitro Diagnostics Market
- 3.2.1 Middle East and Africa In-vitro Diagnostics Market Historical Value (2017-2023)
- 3.2.2 Middle East and Africa In-vitro Diagnostics Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Middle East and Africa In-vitro Diagnostics Market Landscape\*
- 5.1 Middle East and Africa In-vitro Diagnostics: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Country
- 5.2 Middle East and Africa In-vitro Diagnostics: Product Landscape
- 5.2.1 Analysis by Product Type
- 5.2.2 Analysis by Technology
- 5.2.3 Analysis by Therapeutic Area

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.4□Analysis by End User
- 6□Middle East and Africa In-vitro Diagnostics Market Dynamics
  - 6.1□Market Drivers and Constraints
  - 6.2□SWOT Analysis
    - 6.2.1□Strengths
    - 6.2.2□Weaknesses
    - 6.2.3□Opportunities
    - 6.2.4□Threats
  - 6.3□PESTEL Analysis
    - 6.3.1□Political
    - 6.3.2□Economic
    - 6.3.3□Social
    - 6.3.4□Technological
    - 6.3.5□Legal
    - 6.3.6□Environment
  - 6.4□Porter's Five Forces Model
    - 6.4.1□Bargaining Power of Suppliers
    - 6.4.2□Bargaining Power of Buyers
    - 6.4.3□Threat of New Entrants
    - 6.4.4□Threat of Substitutes
    - 6.4.5□Degree of Rivalry
  - 6.5□Key Demand Indicators
  - 6.6□Key Price Indicators
  - 6.7□Industry Events, Initiatives, and Trends
  - 6.8□Value Chain Analysis
- 7□Middle East and Africa In-vitro Diagnostics Market: Trade Data Analysis (HS Code- 38220090)
  - 7.1□Major Exporting Countries
    - 7.1.1□By Value
    - 7.1.2□By Volume
  - 7.2□Major Importing Countries
    - 7.2.1□By Value
    - 7.2.2□By Volume
- 8□Middle East and Africa In-vitro Diagnostics Market Segmentation (2017-2032)
  - 8.1□Middle East and Africa In-vitro Diagnostics Market (2017-2032) by Product Type
    - 8.1.1□Market Overview
    - 8.1.2□Reagents and Kits
    - 8.1.3□Instruments
    - 8.1.4□Software and Services
  - 8.2□Middle East and Africa In-vitro Diagnostics Market (2017-2032) by Technology
    - 8.2.1□Market Overview
    - 8.2.2□Immunoassay/ Immunochemistry
    - 8.2.3□Clinical Chemistry
    - 8.2.4□Molecular Diagnostics
    - 8.2.5□Haematology
    - 8.2.6□Microbiology
    - 8.2.7□Blood Glucose Self-Monitoring
    - 8.2.8□Coagulation and Haemostasis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.2.9 Urinalysis
- 8.2.10 Others
- 8.3 Middle East and Africa In-vitro Diagnostics Market (2017-2032) by Therapeutic Area
  - 8.3.1 Market Overview
  - 8.3.2 Infectious Diseases
    - 8.3.3 Diabetes
    - 8.3.4 Cardiology
    - 8.3.5 Oncology
    - 8.3.6 Autoimmune Diseases
    - 8.3.7 Nephrology
    - 8.3.8 Others
- 8.4 Middle East and Africa In-vitro Diagnostics Market (2017-2032) by End User
  - 8.4.1 Market Overview
  - 8.4.2 Hospitals
  - 8.4.3 Laboratories
  - 8.4.4 Homecare
  - 8.4.5 Others
- 8.5 Middle East and Africa In-vitro Diagnostics Market (2017-2032) by Country
  - 8.5.1 Market Overview
  - 8.5.2 Saudi Arabia
  - 8.5.3 United Arab Emirates
  - 8.5.4 Nigeria
  - 8.5.5 South Africa
  - 8.5.6 Others
- 9 Saudi Arabia In-vitro Diagnostics Market Segmentation (2017-2032)
  - 9.1 Saudi Arabia In-vitro Diagnostics Market (2017-2032) by Product Type
    - 9.1.1 Market Overview
    - 9.1.2 Reagents and Kits
    - 9.1.3 Instruments
    - 9.1.4 Software and Services
  - 9.2 Saudi Arabia In-vitro Diagnostics Market (2017-2032) by Technology
    - 9.2.1 Market Overview
    - 9.2.2 Immunoassay/ Immunochemistry
      - 9.2.3 Clinical Chemistry
      - 9.2.4 Molecular Diagnostics
      - 9.2.5 Haematology
      - 9.2.6 Microbiology
      - 9.2.7 Blood Glucose Self-Monitoring
      - 9.2.8 Coagulation and Haemostasis
      - 9.2.9 Urinalysis
      - 9.2.10 Others
  - 9.3 Saudi Arabia In-vitro Diagnostics Market (2017-2032) by Therapeutic Area
    - 9.3.1 Market Overview
    - 9.3.2 Infectious Diseases
      - 9.3.3 Diabetes
      - 9.3.4 Cardiology
      - 9.3.5 Oncology

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3.6 Autoimmune Diseases
- 9.3.7 Nephrology
- 9.3.8 Others
- 9.4 Saudi Arabia In-vitro Diagnostics Market (2017-2032) by End User
  - 9.4.1 Market Overview
  - 9.4.2 Hospitals
  - 9.4.3 Laboratories
  - 9.4.4 Homecare
  - 9.4.5 Others
- 10 United Arab Emirates Germany In-vitro Diagnostics Market Segmentation (2017-2032)
  - 10.1 United Arab Emirates In-vitro Diagnostics Market (2017-2032) by Product Type
    - 10.1.1 Market Overview
    - 10.1.2 Reagents and Kits
    - 10.1.3 Instruments
    - 10.1.4 Software and Services
  - 10.2 United Arab Emirates In-vitro Diagnostics Market (2017-2032) by Technology
    - 10.2.1 Market Overview
    - 10.2.2 Immunoassay/ Immunochemistry
    - 10.2.3 Clinical Chemistry
    - 10.2.4 Molecular Diagnostics
    - 10.2.5 Haematology
    - 10.2.6 Microbiology
    - 10.2.7 Blood Glucose Self-Monitoring
    - 10.2.8 Coagulation and Haemostasis
    - 10.2.9 Urinalysis
    - 10.2.10 Others
  - 10.3 United Arab Emirates In-vitro Diagnostics Market (2017-2032) by Therapeutic Area
    - 10.3.1 Market Overview
    - 10.3.2 Infectious Diseases
    - 10.3.3 Diabetes
    - 10.3.4 Cardiology
    - 10.3.5 Oncology
    - 10.3.6 Autoimmune Diseases
    - 10.3.7 Nephrology
    - 10.3.8 Others
  - 10.4 United Arab Emirates In-vitro Diagnostics Market (2017-2032) by End User
    - 10.4.1 Market Overview
    - 10.4.2 Hospitals
    - 10.4.3 Laboratories
    - 10.4.4 Homecare
    - 10.4.5 Others
- 11 Nigeria In-vitro Diagnostics Market Segmentation (2017-2032)
  - 11.1 Nigeria In-vitro Diagnostics Market (2017-2032) by Product Type
    - 11.1.1 Market Overview
    - 11.1.2 Reagents and Kits
    - 11.1.3 Instruments
    - 11.1.4 Software and Services

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.2 Nigeria In-vitro Diagnostics Market (2017-2032) by Technology
  - 11.2.1 Market Overview
  - 11.2.2 Immunoassay/ Immunochemistry
  - 11.2.3 Clinical Chemistry
  - 11.2.4 Molecular Diagnostics
  - 11.2.5 Haematology
  - 11.2.6 Microbiology
  - 11.2.7 Blood Glucose Self-Monitoring
  - 11.2.8 Coagulation and Haemostasis
  - 11.2.9 Urinalysis
  - 11.2.10 Others
- 11.3 Nigeria In-vitro Diagnostics Market (2017-2032) by Therapeutic Area
  - 11.3.1 Market Overview
  - 11.3.2 Infectious Diseases
  - 11.3.3 Diabetes
  - 11.3.4 Cardiology
  - 11.3.5 Oncology
  - 11.3.6 Autoimmune Diseases
  - 11.3.7 Nephrology
  - 11.3.8 Others
- 11.4 Nigeria In-vitro Diagnostics Market (2017-2032) by End User
  - 11.4.1 Market Overview
  - 11.4.2 Hospitals
  - 11.4.3 Laboratories
  - 11.4.4 Homecare
  - 11.4.5 Others
- 12 South Africa In-vitro Diagnostics Market Segmentation (2017-2032)
  - 12.1 South Africa In-vitro Diagnostics Market (2017-2032) by Product Type
    - 12.1.1 Market Overview
    - 12.1.2 Reagents and Kits
    - 12.1.3 Instruments
    - 12.1.4 Software and Services
  - 12.2 South Africa In-vitro Diagnostics Market (2017-2032) by Technology
    - 12.2.1 Market Overview
    - 12.2.2 Immunoassay/ Immunochemistry
    - 12.2.3 Clinical Chemistry
    - 12.2.4 Molecular Diagnostics
    - 12.2.5 Haematology
    - 12.2.6 Microbiology
    - 12.2.7 Blood Glucose Self-Monitoring
    - 12.2.8 Coagulation and Haemostasis
    - 12.2.9 Urinalysis
    - 12.2.10 Others
  - 12.3 South Africa In-vitro Diagnostics Market (2017-2032) by Therapeutic Area
    - 12.3.1 Market Overview
    - 12.3.2 Infectious Diseases
    - 12.3.3 Diabetes

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.3.4 Cardiology
- 12.3.5 Oncology
- 12.3.6 Autoimmune Diseases
- 12.3.7 Nephrology
- 12.3.8 Others
- 12.4 South Africa In-vitro Diagnostics Market (2017-2032) by End User
  - 12.4.1 Market Overview
  - 12.4.2 Hospitals
  - 12.4.3 Laboratories
  - 12.4.4 Homecare
  - 12.4.5 Others
- 13 Regulatory Framework
  - 13.1 Regulatory Overview
  - 13.2 Saudi Food and Drug Authority
- 14 Patent Analysis
  - 14.1 Analysis by Type of Patent
  - 14.2 Analysis by Publication Year
  - 14.3 Analysis by Issuing Authority
  - 14.4 Analysis by Patent Age
  - 14.5 Analysis by CPC Analysis
  - 14.6 Analysis by Patent Valuation
  - 14.7 Analysis by Key Players
- 15 Strategic Initiative
  - 15.1 Analysis by Partnership Instances
  - 15.2 Analysis by Type of Partnership
  - 15.3 Analysis by Leading Players
  - 15.4 Analysis by Geography
- 16 Supplier Landscape
  - 16.1 Market Share Analysis, By Region (Top 5 Companies)
    - 16.1.1 Market Share Analysis: Middle East and Africa
  - 16.2 F. Hoffmann-La Roche Ltd
    - 16.2.1 Financial Analysis
    - 16.2.2 Product Portfolio
    - 16.2.3 Demographic Reach and Achievements
    - 16.2.4 Mergers and Acquisitions
    - 16.2.5 Certifications
  - 16.3 Becton, Dickinson and Company
    - 16.3.1 Financial Analysis
    - 16.3.2 Product Portfolio
    - 16.3.3 Demographic Reach and Achievements
    - 16.3.4 Mergers and Acquisitions
    - 16.3.5 Certifications
  - 16.4 Bio-Rad Laboratories, Inc .
    - 16.4.1 Financial Analysis
    - 16.4.2 Product Portfolio
    - 16.4.3 Demographic Reach and Achievements
    - 16.4.4 Mergers and Acquisitions

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 16.4.5□Certifications
- 16.5□ Siemens Healthineers AG
  - 16.5.1□Financial Analysis
  - 16.5.2□Product Portfolio
  - 16.5.3□Demographic Reach and Achievements
  - 16.5.4□Mergers and Acquisitions
  - 16.5.5□Certifications
- 16.6□bioMerieux SA
  - 16.6.1□Financial Analysis
  - 16.6.2□Product Portfolio
  - 16.6.3□Demographic Reach and Achievements
  - 16.6.4□Mergers and Acquisitions
  - 16.6.5□Certifications
- 16.7□Abbott Laboratories
  - 16.7.1□Financial Analysis
  - 16.7.2□Product Portfolio
  - 16.7.3□Demographic Reach and Achievements
  - 16.7.4□Mergers and Acquisitions
  - 16.7.5□Certifications
- 16.8□Quidel Corporation
  - 16.8.1□Financial Analysis
  - 16.8.2□Product Portfolio
  - 16.8.3□Demographic Reach and Achievements
  - 16.8.4□Mergers and Acquisitions
  - 16.8.5□Certifications
- 16.9□OraSure Technologies, Inc .
  - 16.9.1□Financial Analysis
  - 16.9.2□Product Portfolio
  - 16.9.3□Demographic Reach and Achievements
  - 16.9.4□Mergers and Acquisitions
  - 16.9.5□Certifications
- 16.10□Thermo Fisher Scientific Inc
  - 16.10.1□Financial Analysis
  - 16.10.2□Product Portfolio
  - 16.10.3□Demographic Reach and Achievements
  - 16.10.4□Mergers and Acquisitions
  - 16.10.5□Certifications
- 16.11□Hologic, Inc .
  - 16.11.1□Financial Analysis
  - 16.11.2□Product Portfolio
  - 16.11.3□Demographic Reach and Achievements
  - 16.11.4□Mergers and Acquisitions
  - 16.11.5□Certifications
- 16.12□Cepheid Inc (Danaher Corp .)
  - 16.12.1□Financial Analysis
  - 16.12.2□Product Portfolio
  - 16.12.3□Demographic Reach and Achievements

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

16.12.4 Mergers and Acquisitions  
16.12.5 Certifications  
16.13 Illumina, Inc  
16.13.1 Financial Analysis  
16.13.2 Product Portfolio  
16.13.3 Demographic Reach and Achievements  
16.13.4 Mergers and Acquisitions  
16.13.5 Certifications  
17 Middle East and Africa In-vitro Diagnostics Market - Distribution Model (Additional Insight)  
17.1 Overview  
17.2 Potential Distributors  
17.3 Key Parameters for Distribution Partner Assessment  
18 Key Opinion Leaders (KOL) Insights (Additional Insight)  
\*Additional insights provided are customisable as per client requirements.

\* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

\*\*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Middle East and Africa In-vitro Diagnostics Market Report and Forecast 2024-2032**

Market Report | 2024-09-30 | 150 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$3999.00
	Five User License	\$5299.00
	Corporate License	\$6299.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com